Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Docetaxol; NSC 628503; RP 56976; Taxotere; XPR 6976; XRP-6976

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer Roche; Sanofi; University of Iowa; University of Texas M. D. Anderson Cancer Center; West German Study Group
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
  • Registered Solid tumours
  • Phase I/II Sarcoma
  • Discontinued Fallopian tube cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 26 Jan 2018 Sanofi completes a phase III trial in Head and neck cancer (Late stage disease, Neoadjuvant therapy, Combination therapy, Inoperable/Unresectable) in China (IV) (NCT00995293)
  • 22 Aug 2017 Genentech completes a phase I/II trial in Sarcoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, First-line therapy, Second-line therapy or greater, In adults, In the elderly) in USA (unspecified route) (NCT01106872)
  • 02 Jun 2017 Adverse events and efficacy data from the phase-II DECIDE trial in Head and neck cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top